3-Isopropylmalic Acid

Identification

Generic Name
3-Isopropylmalic Acid
DrugBank Accession Number
DB04279
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 176.168
Monoisotopic: 176.068473486
Chemical Formula
C7H12O5
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UIsocitrate dehydrogenase [NADP]Not AvailableEscherichia coli (strain K12)
U3-isopropylmalate dehydrogenaseNot AvailableThiobacillus ferrooxidans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as hydroxy fatty acids. These are fatty acids in which the chain bears a hydroxyl group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acids and conjugates
Direct Parent
Hydroxy fatty acids
Alternative Parents
Short-chain hydroxy acids and derivatives / Methyl-branched fatty acids / Beta hydroxy acids and derivatives / Dicarboxylic acids and derivatives / Alpha hydroxy acids and derivatives / Secondary alcohols / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Alcohol / Aliphatic acyclic compound / Alpha-hydroxy acid / Beta-hydroxy acid / Branched fatty acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Dicarboxylic acid or derivatives / Hydrocarbon derivative
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
2-hydroxydicarboxylic acid (CHEBI:35114)
Affected organisms
Not Available

Chemical Identifiers

UNII
29405QVM5W
CAS number
Not Available
InChI Key
RNQHMTFBUSSBJQ-UHFFFAOYSA-N
InChI
InChI=1S/C7H12O5/c1-3(2)4(6(9)10)5(8)7(11)12/h3-5,8H,1-2H3,(H,9,10)(H,11,12)
IUPAC Name
2-hydroxy-3-(propan-2-yl)butanedioic acid
SMILES
CC(C)C(C(O)C(O)=O)C(O)=O

References

General References
Not Available
PubChem Compound
36
PubChem Substance
46509193
ChemSpider
35
ChEBI
35114
PDBe Ligand
IPM

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility83.3 mg/mLALOGPS
logP0.28ALOGPS
logP0.16Chemaxon
logS-0.33ALOGPS
pKa (Strongest Acidic)3.68Chemaxon
pKa (Strongest Basic)-4Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area94.83 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity38.6 m3·mol-1Chemaxon
Polarizability16.4 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.6224
Blood Brain Barrier+0.7236
Caco-2 permeable-0.8392
P-glycoprotein substrateNon-substrate0.6689
P-glycoprotein inhibitor INon-inhibitor0.958
P-glycoprotein inhibitor IINon-inhibitor0.9708
Renal organic cation transporterNon-inhibitor0.9691
CYP450 2C9 substrateNon-substrate0.8489
CYP450 2D6 substrateNon-substrate0.9047
CYP450 3A4 substrateNon-substrate0.6772
CYP450 1A2 substrateNon-inhibitor0.9618
CYP450 2C9 inhibitorNon-inhibitor0.7235
CYP450 2D6 inhibitorNon-inhibitor0.9486
CYP450 2C19 inhibitorNon-inhibitor0.9661
CYP450 3A4 inhibitorNon-inhibitor0.8998
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9851
Ames testNon AMES toxic0.9387
CarcinogenicityNon-carcinogens0.6052
BiodegradationReady biodegradable0.8725
Rat acute toxicity1.5818 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9949
hERG inhibition (predictor II)Non-inhibitor0.9704
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0006-9400000000-a5c729805d94db1fb7b3
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0002-1920000000-4f96bc5fa684aca3cf53
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03yu-1900000000-aff685381a15f91f0ff9
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-01qi-3900000000-1664532b085152d2ba6c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-9600000000-d26769a9a7aec4f8fddf
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-9600000000-bfe28c6e6e87223d4932
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0019-9000000000-a068ff67f9cb71a9428a
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4r-9000000000-3a63db7b51721e76bf7d
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-139.1697443
predicted
DarkChem Lite v0.1.0
[M-H]-129.91815
predicted
DeepCCS 1.0 (2019)
[M+H]+140.2622443
predicted
DarkChem Lite v0.1.0
[M+H]+133.74733
predicted
DeepCCS 1.0 (2019)
[M+Na]+138.8619443
predicted
DarkChem Lite v0.1.0
[M+Na]+142.94308
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Nad binding
Specific Function
Not Available
Gene Name
icd
Uniprot ID
P08200
Uniprot Name
Isocitrate dehydrogenase [NADP]
Molecular Weight
45756.335 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
Kind
Protein
Organism
Thiobacillus ferrooxidans
Pharmacological action
Unknown
General Function
Nad binding
Specific Function
Catalyzes the oxidation of 3-carboxy-2-hydroxy-4-methylpentanoate (3-isopropylmalate) to 3-carboxy-4-methyl-2-oxopentanoate. The product decarboxylates to 4-methyl-2 oxopentanoate. Can also use D-m...
Gene Name
leuB
Uniprot ID
Q56268
Uniprot Name
3-isopropylmalate dehydrogenase
Molecular Weight
38461.785 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52